Photo Credit: Tumeyes

A research team affiliated with Humanitas Research Hospital conducted a retrospective analysis that assessed the effectiveness and safety of novel biological therapies for patients with very severe psoriasis. The study included 40 patients with a mean age of 55.8 years (SD 13.82), predominantly men, who received biological agents for at least 16 weeks. Giovanni Fiorillo and colleagues assessed PASI scores at weeks 16, 52, 104, and 156 and tracked treatment discontinuation rates and adverse events. Biologics resulted in significant improvement, with mean Psoriasis Area and Severity Index (PASI) scores decreasing from 31.6 at baseline to 1.29 at week 156. A substantial proportion of patients achieved PASI90 and PASI100 at various time points, with 85.71% and 42.86% of patients achieving each respective score at week 156. Participants rarely discontinued treatment due to complete remission, and four patients reported mild AEs. Researchers concluded that their findings demonstrate the effectiveness and long-term tolerability of biologics in managing very severe psoriasis.